To Get Full Access :

NCE-1 Intelligence & Market Opportunity

Aqneursa

Levacetylleucine
Neuroprotective
Oral Suspension

Aqneursa is an oral granule formulation for patients aged 4 years and older with Niemann‑Pick disease type C. It improves neurological symptoms like coordination and balance by enhancing mitochondrial and lysosomal function and reducing cholesterol buildup in nerve cells.

Approval Date
24-Sep-24
NCE-1 Date
24-Sep-28
NCE Date
24-Sep-29
Commercial snapshot

Market performance & projections

Revenue ($M)
NA
CAGR (%)
NA
Projected sales, 2026–2032 ($M)
Analyst projection, $M per year
2026
NA
2027
NA
2028
NA
2029
NA
2030
NA
2031
NA
2032
NA
Molecule profile

Details & specifications

Molecule
Levacetylleucine
Innovator
INTRABIO INC
Dosage Form
Oral Suspension
Strength
1 gm/packet
Therapeutic Category
Neuroprotective
Usage
To treat Niemann-Pick disease type C
Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Login With

For full access Sign-up / Sign-in using below Methods:

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?